Please login to the form below

Not currently logged in
Email:
Password:

JAK2 inhibitor

This page shows the latest JAK2 inhibitor news and features for those working in and with pharma, biotech and healthcare.

BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

Inrebic (fedratinib) is the second JAK inhibitor to be approved for myelofibrosis since Incyte’s Jakafi (ruxolitinib) was cleared by the FDA in 2011, and the first new treatment for the ... The approval of Inrebic – a selective JAK2 inhibitor –

Latest news

  • CTI slumps as Servier-partnered lymphoma drug fails CTI slumps as Servier-partnered lymphoma drug fails

    Thankfully for CTI, it’s been making progress on main pipeline candidate pacritinib , an orally-active kinase inhibitor that targets JAK2, FLT3, IRAK1 and CSF1R and is in phase III testing

  • Another R&D flop for Incyte, but Jakafi keeps delivering Another R&D flop for Incyte, but Jakafi keeps delivering

    Incyte is still trying to recover from the mauling it took after its IDO inhibitor epacadostat for cancer failed earlier this year, and yesterday wrote off another programme in ... JAK1/JAK2 inhibitor Jakafi – given in combination with corticosteroids

  • Is acquisitive Celgene now eyeing CAR-T specialist Juno? Is acquisitive Celgene now eyeing CAR-T specialist Juno?

    The rumours have started circulating just a few days after Celgene agreed a deal to acquire San Diego-based start-up Impact Bio, adding to its haematology business with a JAK2 ... inhibitor - fedratinib - in development for myelofibrosis and

  • Celgene boosts haematology pipeline with $7bn Impact Bio deal Celgene boosts haematology pipeline with $7bn Impact Bio deal

    The US biotech is spending $1.1bn in upfront cash to buy Impact Bio and its late-stage drug candidate fedratinib, a JAK2 inhibitor in development for myelofibrosis and polycythaemia vera ... to Incyte and Novartis’ rival JAK inhibitor Jakafi

  • Lilly planning 20 new launches by 2023 Lilly planning 20 new launches by 2023

    The selective JAK1 and JAK2 inhibitor is being co-developed with Incyte and heads up "a robust emerging pipeline of both internal assets and partnered molecules focusing on key pathways and ... Pfizer-partnered NGF inhibitor tanezumab for osteoarthritis

More from news
Approximately 1 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    The headline value contains significant sales milestones linked to performance of Impact's lead phase III stage asset fedratinib, an oral JAK2 kinase inhibitor in development for the treatment of myelofibrosis ... Acquisition company -  remaining 90%. 9

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    232. Cell Therapeutics / Baxter. Licence. JAK2/FLT3 inhibitor pacritinib for solid tumours, joint marketing in US includes an equity purchase.

  • Pharma deals during November 2013 Pharma deals during November 2013

    While Sanofi announced this month that it had discontinued clinical trials of fedratinib (SAR302503), an investigational JAK2 inhibitor, Baxter entered an exclusive global agreement (headline value $172m) to develop and commercialise ... Cell Therapeutics

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Infographics